Inhibition of Fas expression by RNAi modulates 5-fluorouracil-induced apoptosis in HCT116 cells expressing wild-type p53

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1772, Issue 1, 2007, Pages 40-47

  Borralho, Pedro M ^a   Moreira da Silva, Isabel B ^a   Aranha, Márcia M ^a   Albuquerque, Cristina ^b   Nobre Leitão, Carlos ^b   Steer, Clifford J ^c   Rodrigues, Cecília M P ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

5 fluorouracil; Apoptosis; Fas; Mitochondria; p53; siRNA

Indexed keywords

CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; FAS ANTIGEN; FLUOROURACIL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TRYPAN BLUE;

APOPTOSIS; ARTICLE; CELL STRAIN HCT116; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENSITOMETRY; DRUG CYTOTOXICITY; DRUG RESISTANCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INCUBATION TIME; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; STATISTICAL ANALYSIS; WESTERN BLOTTING; WILD TYPE;

ANTIGENS, CD95; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROURACIL; GENE EXPRESSION; HCT116 CELLS; HUMANS; MITOCHONDRIA; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33845626186     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2006.09.005     Document Type: Article

References (44)

1. Brown J.M., and Wouters B.G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59 (1999) 1391-1399
2. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53 (2002) 615-627
3. Longley D.B., Harkin D.P., and Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev., Cancer 3 (2003) 330-338
4. Pritchard D.M., Potten C.S., and Hickman J.A. The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia. Cancer Res. 58 (1998) 5453-5465
5. Petak I., Tillman D.M., and Houghton J.A. p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. Clin. Cancer Res. 6 (2000) 4432-4441
6. Longley D.B., Allen W.L., McDermott U., Wilson T.R., Latif T., Boyer J., Lynch M., and Johnston P.G. The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites. Clin. Cancer Res. 10 (2004) 3562-3571
7. Pritchard D.M., Watson A.J., Potten C.S., Jackman A.L., and Hickman J.A. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 1795-1799
8. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler K.W., and Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104 (1999) 263-269
9. Backus H.H., Pinedo H.M., Wouters D., Kuiper C.M., Jansen G., van Groeningen C.J., and Peters G.J. Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates. Oncol. Res. 12 (2000) 231-239
10. Backus H.H., Wouters D., Ferreira C.G., van Houten V.M., Brakenhoff R.H., Pinedo H.M., and Peters G.J. Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines. Eur. J. Cancer 39 (2003) 1310-1317
11. Violette S., Poulain L., Dussaulx E., Pepin D., Faussat A.M., Chambaz J., Lacorte J.M., Staedel C., and Lesuffleur T. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int. J. Cancer 98 (2002) 498-504
12. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat. Rev., Cancer 2 (2002) 594-604
13. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
14. Brown J.M., and Attardi L.D. The role of apoptosis in cancer development and treatment response. Nat. Rev., Cancer 5 (2005) 231-237
15. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
16. Miyashita T., and Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80 (1995) 293-299
17. Nakano K., and Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7 (2001) 683-694
18. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., and Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288 (2000) 1053-1058
19. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., Nishimori H., Tamai K., Tokino T., Nakamura Y., and Taya Y. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102 (2000) 849-862
20. Owen-Schaub L.B., Zhang W., Cusack J.C., Angelo L.S., Santee S.M., Fujiwara T., Roth J.A., Deisseroth A.B., Zhang W.W., Kruzel E., et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol. 15 (1995) 3032-3040
21. Miyashita T., Krajewski S., Krajewska M., Wang H.G., Lin H.K., Liebermann D.A., Hoffman B., and Reed J.C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9 (1994) 1799-1805
22. Kho P.S., Wang Z., Zhuang L., Li Y., Chew J.L., Ng H.H., Liu E.T., and Yu Q. p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J. Biol. Chem. 279 (2004) 21183-21192
23. Mihara M., Erster S., Zaika A., Petrenko O., Chittenden T., Pancoska P., and Moll U.M. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 11 (2003) 577-590
24. Moll U.M., Wolff S., Speidel D., and Deppert W. Transcription-independent pro-apoptotic functions of p53. Curr. Opin. Cell Biol. 17 (2005) 631-636
25. Matsuhashi N., Saio M., Matsuo A., Sugiyama Y., and Saji S. p53 dependence and apoptosis in response to FP treatment with p53-transfected colon cancer cell lines by use of thin layer collagen gel. Oncol. Rep. 12 (2004) 357-361
26. Elsaleh H., Powell B., Soontrapornchai P., Joseph D., Goria F., Spry N., and Iacopetta B. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology 58 (2000) 52-59
27. Allegra C.J., Parr A.L., Wold L.E., Mahoney M.R., Sargent D.J., Johnston P., Klein P., Behan K., O'Connell M.J., Levitt R., Kugler J.W., Tria Tirona M., and Goldberg R.M. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J. Clin. Oncol. 20 (2002) 1735-1743
28. Samowitz W.S., Curtin K., Ma K.N., Edwards S., Schaffer D., Leppert M.F., and Slattery M.L. Prognostic significance of p53 mutations in colon cancer at the population level. Int. J. Cancer 99 (2002) 597-602
29. Westra J.L., Schaapveld M., Hollema H., de Boer J.P., Kraak M.M., de Jong D., ter Elst A., Mulder N.H., Buys C.H., Hofstra R.M., and Plukker J.T. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J. Clin. Oncol. 23 (2005) 5635-5643
30. Garrity M.M., Burgart L.J., Mahoney M.R., Windschitl H.E., Salim M., Wiesenfeld M., Krook J.E., Michalak J.C., Goldberg R.M., O'Connell M.J., Furth A.F., Sargent D.J., Murphy L.M., Hill E., Riehle D.L., Meyers C.H., and Witzig T.E. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 22 (2004) 1572-1582
31. Giaccia A.J., and Kastan M.B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12 (1998) 2973-2983
32. Johnstone R.W., Ruefli A.A., and Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108 (2002) 153-164
33. von Haefen C., Gillissen B., Hemmati P.G., Wendt J., Guner D., Mrozek A., Belka C., Dorken B., and Daniel P.T. Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene 23 (2004) 8320-8332
34. McDermott U., Longley D.B., Galligan L., Allen W., Wilson T., and Johnston P.G. Effect of p53 status and STAT1 on chemotherapy-induced Fas-mediated apoptosis in colorectal cancer. Cancer Res. 65 (2005) 8951-8960
35. Muller M., Wilder S., Bannasch D., Israeli D., Lehlbach K., Li-Weber M., Friedman S.L., Galle P.R., Stremmel W., Oren M., and Krammer P.H. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188 (1998) 2033-2045
36. Rich T., Allen R.L., and Wyllie A.H. Defying death after DNA damage. Nature 407 (2000) 777-783
37. Fridman J.S., and Lowe S.W. Control of apoptosis by p53. Oncogene 22 (2003) 9030-9040
38. Marchenko N.D., Zaika A., and Moll U.M. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J. Biol. Chem. 275 (2000) 16202-16212
39. Rampino N., Yamamoto H., Ionov Y., Li Y., Sawai H., Reed J.C., and Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275 (1997) 967-969
40. Luo X., Budihardjo I., Zou H., Slaughter C., and Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94 (1998) 481-490
41. Gross A., Yin X.M., Wang K., Wei M.C., Jockel J., Milliman C., Erdjument-Bromage H., Tempst P., and Korsmeyer S.J. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J. Biol. Chem. 274 (1999) 1156-1163
42. Talos F., Petrenko O., Mena P., and Moll U.M. Mitochondrially targeted p53 has tumor suppressor activities in vivo. Cancer Res. 65 (2005) 9971-9981
43. Schuler M., Bossy-Wetzel E., Goldstein J.C., Fitzgerald P., and Green D.R. p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J. Biol. Chem. 275 (2000) 7337-7342
44. Zhang L., Yu J., Park B.H., Kinzler K.W., and Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 290 (2000) 989-992